Taken together, our study demonstrates that our B7-H3-targeting mAb containing the SDIE modification to enhance ADCC, effectively induces anti-tumor immunity in pancreatic cancer, indicating that B7-H3-SDIE constitutes a promising novel option for pancreatic cancer treatment. Here, CD276 is linked to pancreatic neoplasm.